Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
BioNTech SE
Mirati Therapeutics Inc.
AbbVie
AbbVie
Second Affiliated Hospital of Nanchang University
SWOG Cancer Research Network
Rigshospitalet, Denmark
Cancer Research UK
Hansoh BioMedical R&D Company
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Intergroupe Francophone de Cancerologie Thoracique
Hunan Province Tumor Hospital
Chang Gung Memorial Hospital